Genmab Us Patent-Cliff Exposure & CMS Drug Spending Portfolio

Genmab Us (US): 1 reconciled FDA prescription therapies, $3.8M 2024 CMS Part D & Medicaid spend, and $15,226 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies1
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE DateMulti-asset schedule
2024 CMS Total Public Spend$3.8M
2024 Medicare Part D Spend$1.2M
2024 Medicaid Spend$2.6M
California HCAI SB 17 FilingsSpecialty launch notice ($15,226 intro WAC)